Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Bayer will present new data from its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco, ...

36 In this study, most common SAEs were CRS, cytopenias (thrombocytopenia, neutropenia, and anemia), and rash. Of note, standard-dose LDR was associated with higher incidence of CRS versus ...

Serious adverse reactions reported with acalabrutinib plus BR during the trial were pneumonia, COVID-19, pyrexia, second primary malignancy, rash, febrile neutropenia, atrial fibrillation ...

OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...

Pneumonia, COVID-19, pyrexia, second primary malignancy, rash, febrile neutropenia, atrial fibrillation, sepsis, and anemia occurred in at least 2% of patients. Single-agent acalabrutinib received ...

If approved by the EMA, mavorixafor would be the first drug indicated for patients with WHIM syndrome in Europe, a population ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...

Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common ...

The most common AEs of any grade were cytokine release syndrome (79%), neutropenia (73%), taste changes (65%), skin AEs excluding rash (61%), anemia (56%), nail-related AEs (52%), and pyrexia (51%).